Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy.
Saved in:
| Title: | Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy. |
|---|---|
| Authors: | Resende Salgado L; Department of Radiation Oncology, Mount Sinai Hospital, New York, NY. Electronic address: lucas.resendesalgado@mountsinai.org., Rhome R; Indiana University, Department of Radiation Oncology, Simon Cancer Center, Indianapolis, IN., Oh W; Division of Hematology and Medical Oncology, Mount Sinai Hospital, New York, NY., Stone N; Department of Urology, Mount Sinai Hospital, New York, NY., Stock R; Department of Radiation Oncology, Mount Sinai Hospital, New York, NY. |
| Source: | Brachytherapy [Brachytherapy] 2018 Nov - Dec; Vol. 17 (6), pp. 874-881. Date of Electronic Publication: 2018 Jul 27. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier, 2002- Country of Publication: United States NLM ID: 101137600 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-1449 (Electronic) Linking ISSN: 15384721 NLM ISO Abbreviation: Brachytherapy Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
